Elucidation of a novel pathogenomic mechanism using genome-wide long mate-pair sequencing of a congenital t(16;21) in a series of three RUNX1-mutated FPD/AML pedigrees Familial platelet disorder with propensity to develop myeloid malignancy (FPD/AML OMIM 601399) is an autosomal disorder characterized by quantitative and qualitative platelet anomalies and predisposition to MDS/AML, caused by germ line point mutations, deletions and duplications in RUNX1.
1-4 RUNX1 encodes a transcription factor essential for definitive hematopoiesis, containing an amino-terminal DNA binding domain (RUNT) and a carboxyl-terminal transactivation domain (TA). RUNX1 mutations act by either a dominant negatively interfering mechanism or by haploinsufficiency. Constitutional deletions spanning RUNX1 have been reported in isolated congenital or syndromic thrombocytopenia, stipulating copy number analysis (CNA) of RUNX1 next to sequencing. [5] [6] [7] [8] Given clinical heterogeneity, vigilance in diagnosing FPD/AML is required, reducing the risk of stem cell transplantation (SCT) with carrier siblings. 2, 3 Furthermore, the identification of a RUNX1 abnormality and the elucidation of the underlying pathogenomic mechanism may have implications for genetic counseling for recurrence risk of FPD/AML. This study included two families with classical FPD/AML and one seemingly isolated case with storage pool deficiency (SPD), thrombocytopenia and AML. All patients were of Caucasian origin. For detailed clinical and hematological characteristics of the pedigrees, we refer to Supplemental Table S1 . RUNX1 was analyzed by Sanger sequencing of coding exons 2-9 of gDNA using intronic primers.
In pedigree 1, gDNA was extracted from peripheral blood (PB) of III-2, III-3 and IV-1. A c.508 G4A was detected in RUNX1c exon 4 in affected family members III-2 and IV-1 causing an amino-acid substitution p.Gly170Arg (Figure 1 ), which is located in the RUNT domain. Somatic mutations within this codon have been reported in sporadic AML/MDS. 9 RUNT domain mutations have been related to a negatively interfering mechanism in FPD/AML. 10 The unaffected mother (III-3) as well as DNA from 100 controls lacked the mutation. No DNA was available of the affected daughter V-2 and of IV-3 diagnosed with AML at age of 3 years.
In pedigree 2, sequencing of PB gDNA of III-1, III-5, IV-5 and IV-6 revealed a c.784C4T substitution in RUNX1c exon 6 in all four affected family members causing a premature stop (p.Gln262X) that would result in a truncated RUNX1 protein lacking the TA domain. DNA from 138 controls lacked the mutation. Similar mutations in FPD/AML and sporadic MDS/AML have been reported previously. 3, 10 Interestingly, III-5 developed refractory anemia with excess blast with acquired trisomy 21, recurrently reported in FPD/AML. 2, 4 In the index case of pedigree 3 (III-5), sequencing of RUNX1 on DNA of leukemic bone marrow (BM) did not reveal mutations. gDNA was analyzed using a 105K oligonucleotide array (Agilent, Santa Clara, CA, USA), Oxford design, Amadid 0190015) and the Infinium HumanHap370 Genotyping BeadChip array (Illumina Inc., San Diego, CA, USA) containing 370 000 SNPs with a median probe spacing of 8 kb for copy number changes of RUNX1. These analyses did not disclose unbalance of RUNX1. Uniparental disomy of any chromosome was excluded.
Considering a possible RUNX1 structural abnormality, FISH analysis on leukemic BM was performed, revealing a cryptic t(16;21)(p13;q22) with RUNX1 locus rearrangement in 15 metaphases and 200 interphases ( Figure 2a ). This seminal observation with the patient's hematological history prompted us to investigate RUNX1 status in non-hematopoietic tissues. Interphase FISH analyses on cells from urinary tract epithelium (endoderm) and buccal mucosa (ectoderm), showed RUNX1 locus rearrangement in 86% and 41% of interphases, Accepted article preview online 20 March 2012; advance online publication, 13 April 2012 respectively (Figures 2b and c) . The identification of affected RUNX1 in cells originating from three embryonic germinal layers demonstrated the congenital nature of the t(16;21)(p13;q22). The family was not available to study segregation of the translocation. Family history only revealed a female cousin who suffered from anorexia nervosa and was said to have died of ALL (III-7). No material or records of medical history were available. Therefore, available data suggest the translocation to be de novo, seemingly originated in early embryonic development, and presenting as a congenital mosaicism. The patient was counseled for the potential heritability of the translocation with respect to conceiving offspring affected with FPD/AML and/or chromosomal unbalance, taking into additional account a likely reduced fertility as a result of treatment for AML.
By FISH analyses on BM the 16p13.2 breakpoint was mapped between BAC probes RP11-89D3 and RP11-184P12 distal to ATF7IP2 (Figures 2d-f) . To identify the breakpoints at the molecular level, particularly in RUNX1, we performed genome-wide long mate-pair sequencing analysis (GWLMPS). gDNA was extracted from a residual sample of methanol/acetic acid-fixed chromosome suspension of leukemic BM of the index patient. The suspension was washed twice with 96% ethanol at room temperature, incubated with proteinase K and column purified (DNAeasy kit, Qiagen Benelux, Venlo, The Netherlands). A mate-pair library with an average insert size of 2.8 kb was generated from 5 mg of purified DNA according to the SOLiD 5500 mate-pair protocol (Life Technologies, Carlsbad, CA, USA). The mate-pair library was sequenced on one quadrant of a SOLiD4 instrument (2 Â 50 bp) resulting in an average physical genome coverage of 24 Â . Analysis of mate-pair reads was performed as described. 11 We detected 526 possible fusion points. To remove common structural variations, we filtered our mate-pair results to those of 78 in-house unrelated controls and to the Database of Genomic Variants, reducing the set to 25 unique fusion points (Supplemental Table S2 ). A junction of chr.16p and 21q was identified locating the 16p13.2 breakpoint downstream to coordinate 10 382 445 at B97 kb distal to ATF7IP2, further defining the breakpoint as mapped by FISH (Figures 2f and g , Supplemental Table S2 ). Most importantly, the 21q22.2 breakpoint was localized to intron 1 of RUNX1 (downstream to coordinate 36 301 406) at B39.4 kb distal to RUNX1 exon 2 (Figures 2f and h ). The identification of the breakpoints in a region of RUNX1 with a high content of simple tandem repeats, and in chr.16 with a high density of LINE and SINE repeats, suggests that these sequences may have contributed to the generation of the translocation in our case. It is noteworthy that the highest percentage of breakpoints in acquired t(12;21) ETV6-RUNX1 in childhood ALL have been mapped to this region of RUNX1 intron 1. 12 Genome-wide molecular data on secondary hits in FPD/AML leukemogenesis are spars. Therefore, the data of the 24 additional fusion points are presented in Supplemental Table S2 . They are descriptive and not conclusive, as they could not be related to germ line DNA. Some might be of interest as potential secondary hits; DHX33 is associated with regulation of proliferation, and TMEM66 is associated with apoptosis. Because of opposite transcription orientation, the t(3;16) would not result to an in-frame LHFPL-SLC12A3 fusion gene. None of the listed rearrangements or genes are known to be affected in AML (http://cgap.nci.nih.gov/Chromosomes/Mitelman).
Based on the available data, a mechanism by which the t(16;21) causes SPD, thrombocytopenia and AML, disruption of RUNX1 expression from one allele resulting in RUNX1 haploinsufficiency seems the most likely. RUNX1 transcription is regulated by two non-redundant promoters (P1 and P2). RUNX1c is transcribed from the distal P1, whereas the proximal P2 drives RUNX1b expression. Recently, the RUNX1 þ 23 hematopoietic enhancer, located in intron 1 and conserved in human, was shown to confer hematopoietic specificity to the P1 and P2 promoters. 13, 14 Promoter P1, the first exon and þ 23 enhancer of RUNX1 are translocated to der(16), separating them from the RUNT and TA domain-coding exons (Figure 2g) . Obviously, this would abrogate RUNX1c expression. In addition, the þ 23 enhancer is disconnected from P2, which constitutes a possible mechanism for perturbation of RUNX1b expression from der(21) in hematopoietic cells. Unfortunately, no mRNA was available to study the expression of RUNX1 in our case. Our observation implies that regulatory elements for transcriptional control in RUNX1 might be affected in hitherto unresolved cases of FPD/AML. Of phenotypic consequences of the apparently balanced 16p breakpoint within a large intergenic region one would not expect, but cannot exclude non-penetrance, which is commensurate with the otherwise normal phenotype. For leukemogenesis, one could theorize the þ 23 enhancer to aberrantly target transcription in hematopoietic cells of nearby genes on 16p, of which ATF7IP2 is involved in proliferation in cancer. 15 Our data underscore the power of GWLMPS to bridge chromosomal breakpoints near highly repetitive DNA sequences. Furthermore, they demonstrate the suitability of methanol/acetic acid-fixed chromosome suspension as a source for gDNA to perform GWLMPS to molecularly identify chromosomal abnormalities of cryopreserved samples.
The major finding in our studies is the identification of a congenital translocation affecting RUNX1 as the likely cause of SPD, thrombocytopenia and AML. This seminal observation has important implications for diagnostics and genetic counseling. A balanced translocation affecting RUNX1 could be missed both by sequencing and CNA. Therefore, we recommend FISH analysis for a RUNX1 rearrangement when sequencing and CNA are inconclusive. It could identify an aberration segregating in the family, or, as in our case, reveal a (potential) founding mutation for FPD/AML. Vigilance in identifying a RUNX1 mutation in patients suspected of FPD/AML is required as allogenic SCT is often the only potentially curative treatment. Given clinical heterogeneity of the disorder, candidate sibling donors should then be investigated for being carrier of the abnormality. Furthermore, a de novo 21q RUNX1 translocation, when present in the germ line of a carrier could be transmitted to the next generation, and could result in FPD/AML, but also in chromosomal unbalanced offspring depending on which derivative chromosomes are segregating.
